TrialAlimentary pharmacology & therapeutics2021

Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.

Rifaat Safadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.